Physician profile
Amber Molnar
NPI 1124499496
$4,343.15
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.52 · 2023: $2,590 · 2024: $1,740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,203 · Food and Beverage: $1,128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,202.98 |
| Food and Beverage | $1,127.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,497.61 | 2024 | Turbohawk |
| Silk Road Medical, INC. | $1,479.43 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Terumo Cardiovascular Systems Corporation | $816.62 | 2023 | Harvest, Virtuosaph Plus With Radial Indication |
| W. L. Gore & Associates, INC. | $151.34 | 2023-2024 | Gore Tag Thoracic Branch Endoprosthesis, Gore Tag Conformable Thoracic Endoprosthesis |
| Novartis Pharmaceuticals Corporation | $68.80 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $50.20 | 2021-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $42.79 | 2023 | Lifevest |
| Kiniksa Pharmaceuticals International, Plc | $39.63 | 2024 | Arcalyst |
| Daiichi Sankyo INC. | $35.89 | 2023-2024 | Injectafer |
| Amgen INC. | $34.88 | 2024 | Repatha |
| Sioux Surgical INC | $32.00 | 2024 | |
| Chiesi USA, INC. | $26.53 | 2024 | Kengreal, Cleviprex |
| Alnylam Pharmaceuticals INC. | $21.02 | 2024 | Amvuttra |
| Merck Sharp & Dohme LLC | $16.91 | 2023 | Verquvo |
| Boston Scientific Corporation | $15.01 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $14.49 | 2023 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Molnar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.